prof. Giel Nijpels, PhD, MD

professor

Giel Nijpels (1949, Alkmaar, the Netherlands) studied medicine at the University of Amsterdam and specialised as a general practitioner. In 1976 he started a Health Center in Hoorn (a town about 50 km above Amsterdam), where he worked as a general practitioner and in 1989 he was one of the initiators of the Hoorn Study, a study of glucose tolerance in the general population. In 1996 is obtained a PhD at the VU Medical Center Amsterdam, this was a study of the Natural History of Impaired Glucose Tolerance, a part of the Hoorn Study. In 1989 he was one of the initiators of the Hoorn Study. In 1996 is started the Diabetes Care System West-Friesland, one of the first diabetes management models in the Netherlands.

Giel Nijpels is professor of General Practice with special attention to Diabetes Care, at the Department of General Practice VU University medical center Amsterdam (2006-present). He is project leader of several scientific projects on the epidemiology and pathophysiology of type 2 diabetes and projects on diabetes prevention and diabetes care programmes. Until is official retirement he was programme director of the research program Lifestyle, Diabetes and Overweight of the EMGO Institute, director of the Diabetes Research Center in Hoorn, director of the Diabetes Care System West-Friesland, chair of the board of the Ketenzorgorganisatie West-Friesland. From January 2009  until February 2014 he was member of the Authorization Committee of the Dutch College of General Practice, and member of the Scientific research Board of the Dutch Diabetes Foundation. He is still chairman of the foundation of Arateus of Cappadocie, and became in May 2016 chairmen of the Network Dementia Noord-Holland Noord, the area of the province North-Holland above the line from Alkmaar to Hoorn with a total population of about 700.00 inhabitants.

His special research focuses are threefold:
-                 epidemiology and pathophysiology of type 2 diabetes
-                 diabetes care  and diabetes care models
-                 elderly care and integrated elderly care.

With respect of the research projects related to the epidemiology and pathophysiology of type 2 diabetes collaboration exists within the DIRECT project (IMI funded project http://www.direct-diabetes.org) Former collaboration was in the RISC group (The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk; www.egir.org). Most of this research in performed in the Hoorn study cohorts.
With respect of the research projects related to diabetes care, national collaboration exists in the Diamant project, focused on the development of prediction models for diabetes related complications. Furthermore collaboration exists with several other international research groups around the development and validation of retinopathy models and diagnostic procedures.
With respect of the elderly care in the SUSTAIN project, funded in the Horizon 2020 EU programme,  a close collaboration exists with the RIVM Bilthoven and 6 other European universities and institutions.

He has 565 publications in peer reviewed journals and his H-index is 57.

Awards:
1996: Dr. F. Gerritsen Award
1998: nomination Paludanus Award
2000: nomination Paludanus Award
2001: nomination DAWN Award
2002: nomination Paludanus Award

Grants from 2012 on:
Cardiovascular risk in type 2 diabetes patients: an innovative dynamic prediction model. Accepted by IDF 2012 (70.100 $)
Guideline-concordant continence care instead of the non-curative use of absorbent products Accepted by ZonMw 2013 (250.000 €).
Improving care for sexual dysfunction in persons with type 2 diabetes. Accepted by DFN 2013 (267.000 €).
An innovative strategy for diagnostic fundoscopy in diabetes patients reduces care use and costs compared to usual care. Accepted by ZonMw 2013 (150.000 €).
Sustainable tailored integrated care for older people in Europe, SUSTAIN. HORIZON 2020 EU 2015 (5,888,487 €)
Tailoring care for type 2 diabetes patients using innovative methods to decrease patient burden, health care use and costs. Accepted by DFN 2015 (250.000 €).
Eigen regie bij dementie. Accepted by ZonMw 2016 (100.000 €)1997